We are doing this research to learn how healthy younger and older adults use two forms of vitamin B3-called nicotinamide mononucleotide (NMN) and nicotinamide (NAM)-to make NAD+. NAD+ is a natural substance that cells need for energy and other important processes. Our goal is to find out how these NAD precursors are absorbed and metabolized and how they raise NAD+ in different tissues.
Who can join? Healthy adults men and women aged 18 to 40 (younger group) or 65 and older (older group) Participants with a body mass index ranging between 19 and 35 No major health issues like diabetes or severe kidney disease
What will happen? Participants will take labeled or unlabeled NMN or NAM by mouth every day for 14 days.
Researchers will collect blood, urine, and stool samples. Researchers also do a small muscle biopsy (under local numbing) twice to check how these NAD precursors raise NAD+ in muscle.
Why is this important? NAD+ levels may drop as people age, and this drop could affect overall health and energy in cells.
A better understanding of how NMN and NAM are metabolized in the body to raise NAD+ levels in both younger and older adults may help us optimize dosing and strategies for raising NAD in older people.
Possible benefits and risks:
Participants may not get any direct health benefit from this study; the main goal is to gather new knowledge.
NMN and NAM appear safe in the doses used. A muscle biopsy may cause soreness or bruising.
Researchers will monitor participants closely for any side effects throughout the study.

Start Date01 Apr 2025

Sponsor / Collaborator

Metro International Biotech LLC

NCT05083546

/ Not yet recruitingPhase 1/2IIT

Testing the Impact of a Combination of Dietary Supplements With Multimodal Effects on Longevity Mechanisms on Reducing Body Weight and Delaying Aging

Mechanisms that drive addiction to sugar rich foods are a major driving factor in the pathogenesis of obesity, which has become one of the most significant health care burdens. The molecular underpinnings of these hedonic mechanisms that drive addiction to sugar are poorly understood. The investigators demonstrated that methylglyoxal (MGO) derived Advanced Glycation Endproducts (AGEs) enhance food intake especially under a high sugar diet. The investigators identified a methylglyoxal (MGO) lowering cocktail, Gly-low, a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine that demonstrates a multimodal effect influencing many pathways related to aging including calorie restriction. Glycation lowering (Gly-low) treatment significantly reduces food intake and weight gain in the db/db mice that lack the leptin receptor. The investigators also extended the lifespan of C57BL/6 mice fed with these compounds starting when they were 24 months old. Based on these results, the investigators hypothesized that methylglyoxal (MGO) lowering cocktail of compounds can be given to adults with obesity, specified as body mass index (BMI) >27, to lower serum and urinary markers of insulin resistance, lower boy mass index (BMI), and lower food intake.

Start Date01 Dec 2024

Sponsor / Collaborator

The University of California, San Francisco

NCT06488625

/ RecruitingPhase 2/3IIT

A Phase II/III, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) for Induction and Maintenance Therapy in Patients with Mild to Moderately Active Ulcerative Colitis

Double-blind, randomised, placebo-controlled phase II / III trial evaluating efficacy and safety of two different doses (2 g/d or 3 g/d) of oral controlled-ileocolonic-release nicotinamide (CICR-NAM) compared to placebo in patients with ulcerative colitis (UC).
The intended therapeutic use of CICR-NAM is to improve intestinal inflammation in adults with UC by topically increasing nicotinamide supply in the ileocolonic region and thus favourably influencing the composition of intestinal microbiota

Start Date12 Sep 2024

Sponsor / Collaborator

Universitätsklinikum Schleswig-Holstein Campus Kiel

[+3]

100 Clinical Results associated with Nicotinamide

100 Translational Medicine associated with Nicotinamide

100 Patents (Medical) associated with Nicotinamide

19,727

Literatures (Medical) associated with Nicotinamide

01 Jun 2025·Separation and Purification Technology

Unraveling the competitive cocrystallization behavior of natural products and impact of intermolecular interactions on their stability

Author: Xu, Li ; Gong, Zhuoshan ; Li, Detao ; Ouyang, Jinbo ; Zhou, Limin ; Heng, Jerry ; Zhao, Yan ; Shehzad, Hamza ; Ning, Zichen

Design of natural product cocrystals and its formation mechanism are of great significance importance to the development of fields such as medicine, food, cosmetics, and agriculture.In this research, alkaloids (theophylline, theobromine) and polyhydroxy natural products (quercetin, resveratrol, naringin) were selected as the research subjects.Through competitive cocrystal experiments, the study explored the stability differences among different cocrystals.Based on theor. calculations, the study determined the hydrogen bonds and π-π bonds within the crystals were identified.Combined with cocrystal structure anal., we discussed the influence of hydrogen bonding networks and π-π stacking modes on cocrystal stability.According to these results, the study correlated the cocrystal stability with void level, establishing the void formula to predict the stability between different cocrystals.Addnl., it summarized the structural unit cell model of natural product cocrystals, revealing formation mechanism of cocrystals, and intuitively demonstrating effect of intermol. interactions on stability of crystal.Finally, we proposed the stability law, establishing a close connection between intermol. interactions, void level, and cocrystal stability, providing a theor. basis for exploring relationship between cocrystal microstructure and stability.

01 May 2025·Dyes and Pigments

Simple and user-friendly nucleolus imaging with ultra-narrow bandwidth red emission carbon dots

Author: Khajeh, Khosro ; Kalji, Seyed-Omid ; Sadeghizadeh, Majid

The nucleolus has emerged as a promising target for cancer diagnosis and therapy, with its imaging being crucial for both fundamental research and clin. applications.Fluorescence imaging is a powerful tool for this purpose.However, its use is limited by the scarcity of fluorescent agents that specifically target the nucleolus and have excellent biocompatibility.Carbon dots (CDs) are becoming a valuable tool for cellular imaging because of their excellent optical properties and low toxicity.In this work, for the first time, ultra-narrow bandwidth emission CDs were synthesized with nicotinamide (NAM) and o-phenylenediamine (o-PDA) for nucleolus imaging.The reaction was carried out at 180° for 8 h in a stainless-steel autoclave, using a facile, low-cost, and one-step solvothermal approach with H₂O/H₂SO₄ as solvent.Prepared CDs emit red emission at 617 nm with an ultra-narrow full width at half maximum (FWHM) of 28.1 nm and quantum yield (QY) of 13%.Moreover, the cytotoxicity assay demonstrated that CDs exhibited excellent biocompatibility with MCF-7 breast cancer cells, even at concentrations as high as 4.5 mg/mL.Finally, fixed and live cell imaging results indicate that prepared CDs show bright red fluorescence in the nucleoli of MCF-7 cells.The results demonstrate the efficacy of prepared CDs in nucleolus imaging, offering a convenient and promising fluorescent probe that can be used for fixed and live cell nucleolus imaging.

01 Apr 2025·Food Chemistry

Physicochemical characteristics and metabolite composition of fish sauce made from large yellow croaker roe enzymatic hydrolysates based on three fermentation temperatures

Article

Author: Zhong, Rongbin ; Shi, Feifei ; Yang, Qian ; Liang, Peng ; Wu, Hua ; Du, Yanyu ; Zheng, Tingting

Large yellow croaker roes were used to make fish sauce using enzymolysis method, and the impact of different fermentation temperatures (25, 32 and 40 °C) on the physicochemical characteristics and metabolite composition was revealed. Results indicated that compared with 25 and 32 °C, the higher contents of total acidity, amino nitrogen, total soluble nitrogen, and the deepening of the nonenzymatic browning degree of fish sauce fermented at 40 °C were obtained. The total volatile basic nitrogen content at 40 °C was lower than 32 °C. The ideal fermentation temperature should be 40 °C. The metabolomics analysis of fish sauce showed that 40 °C significantly increased the abundance of hippuric acid, 3-hydroxy hippuric acid, hydrocinnamic acid and heptanoic acid compared with other temperatures, but decreased trimethylamine N-oxide, 15-methyl palmitic acid, N6-succinyl adenosine and nicotinamide. These results expand the utilization pathways of low-value fish roes, and provide a promising reference for the manufacturing of high-quality fish sauce.

News (Medical) associated with Nicotinamide

28 Jan 2025

·www.prnewswire.com

Debut Unveils AI-powered Ingredient Discovery Platform to Fuel Biotech Innovation for All Beauty Brands Globally through Partner KDC/one

New discovery engine, BeautyORB™ by Debut, will create two novel, peak-performing biotech ingredients each year, giving beauty brands access to game-changing clinical claims and product innovation. Debut's new partnership with contract manufacturer KDC/one enables brands of all sizes to harness the power of biotech. SAN DIEGO, Jan. 28, 2025 /PRNewswire/ -- Debut, the biotech beauty leader, announced today the launch of BeautyORB™, an AI-powered innovation engine that provides a new way to discover novel ingredients for best-in-class claims for beauty brands, from a typical time horizon of several years to two Debut ingredients launched each year. The genomics-based AI platform, which is on par with pharmaceutical-grade technology, has already fueled the creation of groundbreaking ingredients addressing inflammaging, epidermal barrier repair and longevity, with brightening, anti-aging and scalp care ingredients already in the pipeline. Continue Reading Image Credit: Billy Economou, BE Studios "With our advanced AI platform and understanding of skin biology, we can rapidly create brand new ingredients through computational compound prediction. This allows us to activate specific aspects of skin biology while also discovering new or improved cellular pathways for enhanced clinical claims," said Joshua Britton, Ph.D, Founder and CEO of Debut. "We don't have to rely on an array of existing ingredients to test against specific claims, and we don't have to go into the field to find rare ingredients in plants. All this can be done at the click of a button, cutting out years from the innovation cycle and accessing ingredients that no one has seen before. We can turn on and off molecular pathways differently and use AI to discover what molecules can affect those pathways. The result is a rich, proven and growing pipeline of novel ingredients with the strongest clinical results for our customers, allowing brands to win on product performance rather than marketing". BeautyORB™ discovers new ingredients by screening 50 billion molecules for their ability to turn on cellular pathways within skin, a process that has never previously been possible in beauty. Debut's AI platform has already identified three novel, patented ingredients that achieve the highest beauty standards including scientifically-proven, clinically-tested and 100% bio-based ingredients that beat existing benchmarks. These ingredients include: DermCeutical InflammagePRO™: Best-in-class for inflammaging. Decreases inflammatory markers, supports the skin barrier and enhances elasticity. 15X better than niacinamide. DermCeutical Barrier RepairPRO™: Best-in-class for epidermal barrier repair. Defends the skin against damage from environmental aggressors. 30% better than vitamin C for skin damage repair. DermCeutical LongevityPRO™: Best-in-class for cellular longevity. Decreases markers of cellular senescence and helps maintain healthy skin cells. 2X better than vitamin C for skin health. "With BeautyORB™, we can develop ingredients that have the targeted responses we seek, using the same technology to find ingredients that fight disease. Our tool is another key step in the convergence of pharma and beauty. We are thrilled to partner with the industry leading contract manufacturer KDC/one to create finished products of the highest quality, in tandem with Debut's custom formulation business, BiotechXBeautyLabs™, to achieve our mission of reinventing product performance with the safest sustainability credentials. Our KDC/one partnership sets the stage for a global biomanufacturing revolution in beauty," said Britton. BeautyORB™ is the latest tool to emerge from Debut's ongoing commitment to lead the beauty industry's shift to biotech, creating a community of future-forward brands and product innovators that solve existing and emerging consumer needs. Using generative AI, BeautyORB™ delivers: More than 50 billion molecule possibilities 30,000 genes tested per molecule using omics technology 25,000 genes tested per second 21,000 molecules screened in silico per second for deep learning 200+ new biological pathways tested per molecule Over 60 million data points, with 100 million over the next 12 months About Debut The leader in biotech beauty Debut is pioneering the beauty industry's shift from traditionally sourced ingredients derived from petroleum and cultivation to high-performing and inherently sustainable biotech ingredients. As a fully vertically-integrated global company, Debut creates superior, scientifically-engineered, bio-based and clinically-proven products and brands at scale to benefit people and planet. Our mission is to create a new beauty standard based on potency, purity, and performance. About KDC/one Industry leading Contract Manufacturer KDC/one's Beauty & Personal Care manufacturing platform includes state-of-the-art facilities across North America, Europe, and Asia, allowing us to seamlessly deliver solutions for the complex production requirements of our global customers. With a global network of manufacturing, R&D, innovation hubs, and showrooms, KDC/one has end-to-end capabilities across formulation, design, packaging, and manufacturing to service a wide range of customer types, from start-up brands to multinational consumer companies. SOURCE Debut Biotechnology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

11 Dec 2024

·www.prnewswire.com

Elume Offers Fuss-Free Skincare Solutions for All Skin Tones

The Indian Skincare Brand Is Empowering Women Around the World With Simple, Pleasant, Effective Skincare Solutions FORT LAUDERDALE, Fla., Dec. 11, 2024 /PRNewswire/ -- Elume is a forward-thinking skincare company that is empowering women through simple, streamlined, and effective skincare solutions for all skin tones. The breakout Indian brand's inclusive emphasis comes from its focus on its Asian-first philosophy and its desire to meet the unique needs of the Asian consumer. Elume has created its popular and diverse skincare range through a combination of simple choices and thorough education. The company focuses on reducing overwhelm through easily accessible information and positive experiences. "Our goal is to create pleasant, fuss-free experiences for everyone, no matter their skin tone or skincare needs," said Elume co-founder Pavneet. "Élume is more than a skincare brand; it's a celebration of diversity and natural beauty. Our products, enriched with potent ingredients like Vitamin C and Niacinamide, are crafted to meet the unique needs of people with melanated skin, ensuring they receive the care and nourishment their skin deserves." As a way to make the skincare journey easier, Elume has put a heavy emphasis on transparency throughout its business activity. Formulas are easy to find and presented in concise yet comprehensive formats. This makes it easier for customers to make the best choice based on their unique skin needs. In addition, the company has an entire page devoted to ingredient descriptions to further promote education and wise purchase decisions. There is also a clear dual focus on prevention and treatment. Some products help maintain healthy skin, while others address specific concerns and conditions. One of the best examples of Elume's comprehensive and effective approach to global skincare is its Vitamin C+ range. The popular product line includes a cleanser, toner, serum, and moisturizer, all with clear descriptions and applications. The collection is celebrated for brightening and revitalizing the skin and the ability to consistently deliver exceptional results based on clearly communicated expectations. The brand has similar products formulated for skin radiance, acne, hyperpigmentation, and aging skin. Elume is more than a skincare brand. On the surface, its products offer a proactive approach to skincare, ensuring long-term skin wellness and vitality. But it goes further. The company is also committed to exceptional service as it cares for consumers and gives them the confidence to care for their bodies without the need to cover up or alter them. About Elume Elume is a brand from Skin Habits Pvt. Ltd. and was launched in 2021 in the heart of North India, Chandigarh. The company operates with family values and an emphasis on a better tomorrow. This primarily focuses on leaving behind old, harmful ideologies that have resonated for generations. The Elume team has over 20 years of expertise in skincare and embraces an Asian-first philosophy founded on meticulous research in the areas of melanated skin, tropical weather, and a fast-paced lifestyle. Its products are dermatologically tested, PETA-approved cruelty-free, and manufactured at a WHO GMP-certified factory. Learn more at elume.in. Arvin Mondal Director, International Business Development M: +91 991 590 0348 E: [email protected] SOURCE Elume WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

13 Aug 2024

·www.drugs.com

Nicotine Analogue Concentrations Deviate From Labels

TUESDAY, Aug. 13, 2024 -- There are discrepancies between labeled and measured concentrations of nicotine analogues in electronic cigarettes and e-cigarette liquids, according to a research letter published online Aug. 7 in the Journal of the American Medical Association . Hanno C. Erythropel, Ph.D., from Yale University in New Haven, Connecticut, and colleagues quantified constituents of e-cigarette products containing nicotine analogues to assess product consistency. The analysis included nine available flavors of product 1 labeled as containing 5 percent 6-methylnicotine (6MN) and two flavors of product 2 at four concentrations of nicotinamide (0, 12, 24, and 36 mg/mL) that were purchased between November 2023 and February 2024 from three major online retailers. The researchers found that 6MN presence was confirmed in all product 1 flavors. Both nicotinamide and 6MN were detected in product 2 samples labeled as containing nicotinamide (six of eight). No sample contained nicotine. Product 1 was labeled as containing 5 percent 6MN (50 mg/g), but the analysis showed it only contained 5.8 to 6.3 mg/g (87 to 88 percent less than labeled). In product 2, samples contained nicotinamide contents 7 to 46 percent less than as labeled. Although product 2 labels did not list 6MN as an ingredient, 6MN was detected (0.06 to 0.17 mg/g) when nicotinamide was present. Product 1 samples contained only the (S)-6MN stereoisomer, which previous research showed is more potent and addictive than the (R) form. Product 1 samples all contained the artificial sweetener neotame (0.20 to 0.86 mg/g) and the synthetic coolant 2-isopropyl-N-2,3-trimethylbutyramide (WS-23; 4.34 to 16.39 mg/g) plus various flavorants, whereas product 2 samples did not contain sweeteners or coolants. "With e-cigarettes increasingly considered for smoking cessation , the advent of nicotine analogue-containing products with unknown health risks raises concern," the authors write.

Clinical Result

100 Deals associated with Nicotinamide

External Link

KEGG	Wiki	ATC	Drug Bank
D00036	Nicotinamide	A11HA01	DB02701

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Arrhythmias, Cardiac	China	Shanxi Taisheng Pharmaceutical Co., Ltd.	10 Mar 2006
Coronary Artery Disease	China	Shanxi Taisheng Pharmaceutical Co., Ltd.	10 Mar 2006
Myocarditis	China	Shanxi Taisheng Pharmaceutical Co., Ltd.	10 Mar 2006
Vitamin B Deficiency	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	01 Jan 1996
Pellagra	Japan	Catalent Japan KK	27 Oct 1961
Acne Vulgaris	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Discovery	Germany	MEDICE Arzneimittel Pütter GmbH & Co. KG	01 Aug 2010
Hyperphosphatemia	Discovery	Germany	MEDICE Arzneimittel Pütter GmbH & Co. KG	01 Aug 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02416739 (Pubmed) Manual	Phase 2	EGFR Mutation Lung Cancer	110	Nicotinamide	(mtrhfcqbvn) = nqbqxegavg fwqrmepnmd (ryovawkezj, 10.4 - 18.3) View more	Positive	09 Apr 2024
				Placebo	(mtrhfcqbvn) = yhiqdvskwu fwqrmepnmd (ryovawkezj, 9.0 - 13.2) View more
NCT02416739 (AACR2024) Manual	Phase 2	EGFR Mutation Lung Cancer	110	Nicotinamide	(ecmqqkonjk) = vvkspwrkwq revzxfejvd (ruodlwdauv, 10.4 - 18.3) View more	Positive	05 Apr 2024
				Placebo	(ecmqqkonjk) = fclwfdbkcs revzxfejvd (ruodlwdauv, 9.0 - 13.2) View more
NCT03136705 (CTgov)	Phase 1	-	39	Lanthanum Carbonate+Nicotinamide (Lanthanum + Nicotinamide)	shxtiumnxr(siymqpoiqn) = bamvgsmsnj lzqujbkhry (appyxgdvbs, rgpostbcyn - cmnkbzzdgn) View more	-	23 Feb 2024
				Lanthanum Carbonate+Nicotinamide Placebo (Lanthanum + Nicotinamide Placebo)	shxtiumnxr(siymqpoiqn) = zwlevkjjmj lzqujbkhry (appyxgdvbs, swzeaotxqq - iahxxmihis) View more
NCT03061474 (NEAT, CTgov)	Phase 2	Alzheimer Disease \| Mild cognitive disorder	46	Nicotinamide (Nicotinamide)	sogxyritwk(rljcajfoih) = cdfqwdfunp fpswdaubgk (arhdgpzbbv, cqejocgnez - jmjoumtuni) View more	-	17 Oct 2023
				Placebo Comparator (Placebo)	sogxyritwk(rljcajfoih) = edrmjuojcc fpswdaubgk (arhdgpzbbv, jvwhnhkmam - apcgdyzxuh) View more
EADV2023	Not Applicable	Acne Vulgaris	67	Facial night serum with retinaldehyde, zinc PCA, and niacinamide	yhlbalyaff(dkcypxispa) = 4 out of 67 subjects reported mild events ( burning and itching ) in specific applications that receded almost immediately wovckfcdgd (nqvuxkrwrt ) View more	Positive	11 Oct 2023
WCD2023	Not Applicable	-	-	High broad spectrum sunscreen containing Nicotinamide and Panthenol	wvrfmzqhlh(uxaailqkzw) = ywvjmymhgn ycdcolepux (bxntjicwib ) View more	Positive	03 Jul 2023
ACTRN12617000599370 (Pubmed \| N Engl J Med)	Phase 3	Skin Neoplasms	158	Nicotinamide 500 mg	jofvzjrcdg(ewwzqopsho) = pycwgvmoqt tmkdefgeta (elehniqdck )	Negative	02 Mar 2023
				Placebo	jofvzjrcdg(ewwzqopsho) = zvvqeurtik tmkdefgeta (elehniqdck )
NCT03419364 (CTgov)	Phase 2	Pre-Eclampsia	23	nicotinamide (Nicotinamide - Pre-eclampsia)	knzflqmbjo(lflzmvzqqb) = hetyrjbvjb bmfdwdistz (zjddzgpgcj, baloydtqcw - yjwdhdpjfr) View more	-	08 Sep 2022
				nicotinamide (Nicotinamide - Healthy Pregnant)	knzflqmbjo(lflzmvzqqb) = jhfrdxbkwn bmfdwdistz (zjddzgpgcj, gcxsqdpxin - stsvrbvqcz) View more
EADV2022	Not Applicable	Actinic Keratosis p21 positive \| DIMTIM \| p53 ... View more	12	High broad spectrum UVB-UVA sunscreen containing Nicotinamide and Panthenol	zxqhmbtzgl(zifilsycsl) = nlqnpvxvdg wgzzjwvvze (uhmzkksqvw ) View more	Positive	07 Sep 2022
NCT02258074 (COMBINE TRIAL \| COMBINE \| CKD Optimal Management with Binders and Nicotinamide (COMBINE), CTgov)	Phase 2	Chronic Kidney Diseases	205	Lanthanum Carbonate+Nicotinamide (Lanthanum Carbonate + Nicotinamide)	ufncwzqmum(tkfledkygw) = ixrspwsdhi loqqvsjfxa (qfukbvsokd, rcgcqpayir - mwipiugtjx) View more	-	30 Jul 2021
				Lanthanum Carbonate+Placebo (for Nicotinamide) (Lanthanum Carbonate + Nicotinamide Placebo)	ufncwzqmum(tkfledkygw) = grvowcmgwo loqqvsjfxa (qfukbvsokd, lrtcefmhpf - zjwdbgevdb) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis